NRX Pharmaceuticals, Inc.
NRXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001719406
No open-market purchases or sales by NRX Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $47.6M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in NRX Pharmaceuticals, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +3 vs. Q1 2025
- Shares held
- 2.99M
- +733.8K (+32.5%) vs. Q1 2025
- Total value
- $9.76M
- +$5.16M (+112.1%) vs. Q1 2025
- New holders
- 5
- 10 more added
- Sold out
- 2
- 4 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NRXP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 47 | $47.6M |
| Q1 2026 | 33 | $13.2M |
| Q4 2025 | 28 | $14.2M |
| Q3 2025 | 24 | $13.0M |
| Q2 2025 | 25 | $9.76M |
| Q1 2025 | 22 | $4.60M |
| Q4 2024 | 25 | $2.31M |
| Q3 2024 | 18 | $1.21M |
| Q2 2024 | 19 | $1.29M |
| Q1 2024 | 31 | $1.76M |
| Q4 2023 | 30 | $1.84M |
| Q3 2023 | 34 | $964.7K |
| Q2 2023 | 32 | $4.78M |
| Q1 2023 | 30 | $2.07M |
| Q4 2022 | 33 | $3.44M |
| Q3 2022 | 30 | $3.04M |
| Q2 2022 | 37 | $2.18M |
| Q1 2022 | 34 | $25.1M |
| Q4 2021 | 38 | $12.4M |
| Q3 2021 | 23 | $16.2M |
| Q2 2021 | 18 | $18.9M |
| Q1 2021 | 1 | $4.00K |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding NRX Pharmaceuticals, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Anson Funds Management LP | 1,604,975 | $5.23M | 0.96% | +425,914+36.1% | Added |
| Vanguard Group Inc | 452,175 | $1.47M | 0.00% | +63,250+16.3% | Added |
| AdvisorShares Investments LLC | 263,797 | $860.0K | 0.16% | −23,000−8.0% | Reduced |
| Geode Capital Management, LLC | 172,255 | $561.6K | 0.00% | +37,598+27.9% | Added |
| UBS Group AG | 121,608 | $396.4K | 0.00% | +121,503+115,717.1% | Added |
| Citadel Advisors LLC | 92,361 | $301.1K | 0.00% | +92,361 | New |
| BlackRock, Inc. | 64,400 | $209.9K | 0.00% | +35,325+121.5% | Added |
| State Street Corp | 51,084 | $166.5K | 0.00% | +7,360+16.8% | Added |
| Squarepoint Ops LLC | 42,202 | $137.6K | 0.00% | +42,202 | New |
| Marshall Wace, LLP | 33,384 | $108.8K | 0.00% | −55,702−62.5% | Reduced |
| Two Sigma Investments, LP | 31,452 | $102.5K | 0.00% | +1,306+4.3% | Added |
| Northern Trust Corp | 28,601 | $93.2K | 0.00% | 00.0% | Unchanged |
| One Wealth Management Investment & Advisory Services, LLC | 15,041 | $49.0K | 0.06% | 00.0% | Unchanged |
| Morgan Stanley | 4,396 | $14.3K | 0.00% | −7,500−63.0% | Reduced |
| Bank of America Corp | 3,524 | $11.5K | 0.00% | +181+5.4% | Added |
| SBI Securities Co., Ltd. | 3,392 | $11.1K | 0.00% | +1,392+69.6% | Added |
| Group One Trading, L.P. | 3,108 | $10.1K | 0.00% | +3,108 | New |
| Raymond James Financial Inc | 2,571 | $8.38K | 0.00% | +2,571 | New |
| Wells Fargo & Company | 2,000 | $6.52K | 0.00% | −160−7.4% | Reduced |
| Tower Research Capital LLC (TRC) | 1,156 | $3.77K | 0.00% | +1,156 | New |
| Simplex Trading, LLC | 690 | $2.00K | 0.00% | +57+9.0% | Added |
| Advisor Group Holdings, Inc. | 90 | $293 | 0.00% | 00.0% | Unchanged |
| Carolina Wealth Advisors, LLC | 50 | $163 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 34 | $111 | 0.00% | 00.0% | Unchanged |
| Larson Financial Group LLC | 22 | $72 | 0.00% | 00.0% | Unchanged |
| TownSquare Capital, LLC | 0 | $0 | 0.00% | −15,041−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −37−100.0% | Sold out |